Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.


Published on .

Schering-Plough Corp. has awarded its $170 million media buying and planning account for allergy drugs Claritin and Nasonex to Zenith Media Services, New York, a Schering spokesman said.

Interpublic Group of Cos.' Lowe, Lintas & Partners Worldwide, New York, was the incumbent. One executive close to the situation said the client and agency had not had "the most rosy relationship."

Lowe held onto the account in a review last year that Zenith participated in. Zenith eventually is expected to add duties for Clarinex, the successor drug to Claritin that the U.S. Food and Drug Administration has said it will not approve for marketing until Schering fixes manufacturing problems. -- Richard Linnett

Copyright March 2001, Crain Communications Inc.

Most Popular
In this article: